TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Posted on: Friday, 10 August 2007, 00:04 CDT
TAIPEI, Taiwan, Aug. 10 /Xinhua-PRNewswire/ -- TaiGen Biotechnology Inc. announces the successful completion of patient recruitment for the global double-blind Phase II clinical trial of Nemonoxacin (TG-873870) for the treatment of adult community-acquired pneumonia (CAP). A total of 265 patients have been admitted to the trial. Completion of the trial data analysis is expected in the last quarter of 2007. In this trial, the effect of Nemonoxacin in comparison with levofloxacin, the leading quinolone on the market, is evaluated with both clinical and bacteriological success rates in treating adult patients with CAP.
"We are pleased with the efficient manner in which the 18 clinical centers have enrolled patients in the phase II study," said Dr. Ming Chu Hsu, Chairman and CEO of TaiGen. "Completing enrollment in this study shall keep us on track of our projected development timeline for this highly promising antibacterial for the treatments of resistant infection."
About TaiGen Biotechnology Co., LTD
TaiGen Biotechnology (http://www.taigenbiotech.com/ ) is a leading pharmaceutical company based in Taiwan and has a wholly-owned subsidiary in Beijing, China. The company is developing novel therapeutics to treat infectious diseases, diabetic complications and cancer for the worldwide market. TaiGen has a full capacity in new drug R&D and clinical development in China, Taiwan, US and other countries. Nemonoxacin, an once-a-day oral and IV antibacterial active against gram-positive and -negative pathogens and MRSA, will soon to enroll diabetic foot infection patients in a double-blind phase 2 trial. The company has first-in-class phase 1-ready drug candidates for treating critical limb ischemia and retinopathy/age-related macular degeneracy, and advanced preclinical candidates for chronic Hepatitis C virus infection and cancer.
Contact Information: Stephen Ip, Ph.D. SVP Global Business Development Tel: +886-2-2790-1861 Fax: +8862-2790-9962 Email: sip@taigenbiotech.com Add: 7F, 138 Shin Ming Rd., Neihu Dist., Taipei, Taiwan 11470, R.O.C.
TaiGen Biotechnology Co., LTD
CONTACT: Dr. Stephen Ip of TaiGen Biotechnology, +886-2-2790-1861, fax+886-2-2790-9962, sip@taigenbiotech.com
Web site: http://www.taigenbiotech.com/
Source: PRNewswire
Related Articles
- Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
- Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients With Cardiovascular Disease
- Cougar Biotechnology Announces Initiation of Phase III Trial of CB7630 (Abiraterone Acetate)
- Methylgene and Pharmion Start Phase II Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
- MethylGene and Pharmion Initiate Phase I Combination Clinical Trial With MGCD0103 and Taxotere(R) in Patients With Solid Tumors
- InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
- Pharmion Corporation Initiates Phase One/Two Combination Clinical Trial With MGCD0103 and Gemzar(R) in Patients With Pancreatic Cancer
- Ipilimumab (MDX-010) Shows Encouraging Data in Phase I and Phase II Clinical Trials for Hormone Refractory Prostate Cancer Patients
- Cougar Biotechnology Announces Initiation of Phase I/II Trial for CB7630 (Abiraterone Acetate)
 |
 |
User Comments (0)
RSS Feeds